Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
An announcement from Pacific Edge Limited ( (PFGTF) ) is now available.
Pacific Edge Limited reported a 6.8% increase in the number of Cxbladder tests processed in Q4 2025, driven by higher adoption in the US. This growth was supported by an increase in the number of US clinicians ordering the tests and the number of tests per clinician. The inclusion of Cxbladder Triage in the American Urological Association’s guidelines with a ‘Grade A’ evidence rating has positively impacted the company’s sales strategy and generated renewed interest among urology professionals. However, the Asia Pacific region saw a decline in test volumes due to budget constraints and a focus on commercial testing. The company’s annual test volumes decreased by 11.5% due to uncertainties over Medicare coverage.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company based in Dunedin, New Zealand, specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. The company offers its Cxbladder tests, which are urine-based genomic biomarker tests, through its laboratories in New Zealand and the USA.
YTD Price Performance: 12.86%
Average Trading Volume: 16,566
Technical Sentiment Signal: Sell
Current Market Cap: $60.96M
See more data about PFGTF stock on TipRanks’ Stock Analysis page.